{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T11:57:51Z","timestamp":1768219071743,"version":"3.49.0"},"reference-count":24,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T00:00:00Z","timestamp":1768176000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To construct and validate a nomogram prediction model for anxiety and depression in chemotherapy patients with multiple myeloma (MM).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>From May 2021 to May 2023, 333 MM chemotherapy patients treated at our hospital were selected. The patients were randomly divided into a modeling group and a validation group in a 7:3 ratio (using a random number table method). According to whether the modeling group patients had anxiety and depression, they were grouped into a non-anxiety and depression group and an anxiety and depression group; a nomogram model constructed using R software was built to evaluate the predictive performance of the model. Clinical decision curves (DCA) were used to assess the value of the clinical application of the model.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Out of the 233 patients in this study, 66 experienced anxiety and depression, with an incidence rate of 28.33%. There were great differences in gender, economic income, education level, tumor staging, complications, and treatment plans between the anxiety and depression group and the non-anxiety and depression group (P&amp;lt;0.05). The results of multivariate Logistic regression analysis showed that gender, education level, tumor stage, complications, and treatment plan were risk factors for anxiety and depression in MM chemotherapy patients (P&amp;lt;0.05), while economic income served as a protective factor (P&amp;lt;0.05). The AUC of the modeling group was 0.945, and the H-L test was \u03c72 = 8.579, P = 0.674, with good agreement. The AUC of the validation group was 0.967, and the H-L test was \u03c72 = 7.315, P = 0.698, with good consistency. The DCA curve shows that the probability of assessing anxiety and depression in patients undergoing MM chemotherapy is higher for clinical use when the probability is between 0.05 and 0.95.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Gender, education, tumor stage, comorbidities and treatment regimen were risk factors for anxiety and depression in MM chemotherapy patients, while financial income was a protective factor for anxiety and depression in MM chemotherapy patients, and the constructed nomogram visually predicted the risk of anxiety and depression in MM chemotherapy patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fpsyt.2025.1578132","type":"journal-article","created":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T08:43:47Z","timestamp":1768207427000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Construction and validation of nomogram prediction model for anxiety and depression in chemotherapy patients with multiple myeloma"],"prefix":"10.3389","volume":"16","author":[{"given":"Liping","family":"Wu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yizhen","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26590","article-title":"Multiple myeloma: 2022 update on diagnosis, risk stratification, and management","volume":"97","author":"Rajkumar","year":"2022","journal-title":"Am J Hematol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.0003","article-title":"Diagnosis and management of multiple myeloma: A review","volume":"327","author":"Cowan","year":"2022","journal-title":"JAMA"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-019-04984-x","article-title":"Factors influencing supportive care needs of multiple myeloma patients treated with chemotherapy","volume":"28","author":"Cho","year":"2020","journal-title":"Support Care Cancer"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.637593","article-title":"Prevalence of chemotherapy-induced peripheral neuropathy in multiple myeloma patients and its impact on quality of life: A single center cross-sectional study","volume":"12","author":"Selvy","year":"2021","journal-title":"Front Pharmacol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.5630","article-title":"Prognostic nomogram for multiple myeloma early relapse after autologous stem cell transplant in the novel agent era","volume":"12","author":"Zhou","year":"2023","journal-title":"Cancer Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"22424","DOI":"10.1038\/s41598-024-73826-6","article-title":"Visualization obesity risk prediction system based on machine learning","volume":"14","author":"Du","year":"2024","journal-title":"Sci Rep"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2025.1544894","article-title":"Development of a visualized risk prediction system for sarcopenia in older adults using machine learning: a cohort study based on CHARLS","volume":"13","author":"Du","year":"2025","journal-title":"Front Public Health"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2025.1606316","article-title":"A risk prediction system for depression in middle-aged and older adults grounded in machine learning and visualization technology: a cohort study","volume":"13","author":"Du","year":"2025","journal-title":"Front Public Health"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_159009","article-title":"Updated diagnostic criteria and staging system for multiple myeloma","volume":"35","author":"Rajkumar","year":"2016","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyg.2022.1015497","article-title":"Pain as a risk factor of depression and anxiety symptoms with multiple myeloma during maintenance therapy","volume":"13","author":"Shi","year":"2022","journal-title":"Front Psychol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.5694\/mja2.50129","article-title":"Biology and therapy of multiple myeloma","volume":"210","author":"Joshua","year":"2019","journal-title":"Med J Aust"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1186\/s12885-022-10101-9","article-title":"The influence of baseline characteristics, treatment and depression on health-related quality of life in patients with multiple myeloma: a prospective observational study","volume":"22","author":"Fischer","year":"2022","journal-title":"BMC Cancer"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1080\/10376178.2019.1623699","article-title":"Factors influencing quality of life in patients with multiple myeloma","volume":"55","author":"Kang","year":"2019","journal-title":"Contemp Nurse"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1002\/jha2.470","article-title":"Gender disparities in multiple myeloma publications","volume":"3","author":"Dweik","year":"2022","journal-title":"EJHaem"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.5306\/wjco.v14.i4.179","article-title":"Interaction between age and gender on survival outcomes in extramedullary multiple myeloma over the past two decades","volume":"14","author":"Bangolo","year":"2023","journal-title":"World J Clin Oncol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"101415","DOI":"10.1016\/j.jgo.2022.12.003","article-title":"Association of individual low-income status and area deprivation with mortality in multiple myeloma","volume":"14","author":"Hong","year":"2023","journal-title":"J Geriatr Oncol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers13040590","article-title":"Socioeconomic factors and survival of multiple myeloma patients","volume":"13","author":"Chamoun","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B18","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1186\/s12885-020-07178-5","article-title":"Education level as a predictor of survival in patients with multiple myeloma","volume":"20","author":"Xu","year":"2020","journal-title":"BMC Cancer"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.32357","article-title":"Characteristics of long-term survivors with multiple myeloma: A National Cancer Data Base analysis","volume":"125","author":"Hsieh","year":"2019","journal-title":"Cancer"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/medsci9010003","article-title":"Epidemiology, staging, and management of multiple myeloma","volume":"9","author":"Padala","year":"2021","journal-title":"Med Sci (Basel)"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7554\/eLife.75340","article-title":"Revised International Staging System (R-ISS) stage-dependent analysis uncovers oncogenes and potential immunotherapeutic targets in multiple myeloma (MM)","volume":"11","author":"Zhong","year":"2022","journal-title":"Elife"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2020.11.010","article-title":"Management of acute kidney injury in symptomatic multiple myeloma","volume":"99","author":"Bridoux","year":"2021","journal-title":"Kidney Int"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020005288","article-title":"Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial","volume":"136","author":"Voorhees","year":"2020","journal-title":"Blood"},{"key":"B24","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1111\/bjh.18295","article-title":"Lenalidomide, bortezomib and dexamethasone induction therapy for the treatment of newly diagnosed multiple myeloma: a practical review","volume":"199","author":"McCaughan","year":"2022","journal-title":"Br J Haematol"}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2025.1578132\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T08:43:48Z","timestamp":1768207428000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2025.1578132\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,12]]},"references-count":24,"alternative-id":["10.3389\/fpsyt.2025.1578132"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2025.1578132","relation":{},"ISSN":["1664-0640"],"issn-type":[{"value":"1664-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,12]]},"article-number":"1578132"}}